AstraZeneca's SEC Form 6-K reveals promising results for Datroway in metastatic triple-negative breast cancer, showing significant survival improvements in patients not eligible for immunotherapy.
Discover AstraZeneca PLC's latest financial insights, including voting rights and regulatory compliance under Form 20-F. Essential for investors and stakeholders.
Discover AstraZeneca's Enhertu's promising trial results for HER2-positive early breast cancer, showcasing significant survival improvements and plans for regulatory approval.
Discover AstraZeneca PLC's latest Form 6-K detailing voting rights and share capital as of August 31, 2025. Key info for shareholders on compliance and transparency.
AstraZeneca PLC's August 2025 report corrects a TR-1 notification error. Shareholders should refer to the proper TR-1 from 21 August. Find details on their investor relations site.
Explore AstraZeneca PLC's latest Form 6-K, filed on August 1, 2025, detailing 1.55B voting rights and compliance with UK regulations vital for shareholders.
Explore AstraZeneca's Q2 2025 financial report, highlighting $28.045B revenue, 8% growth, and a strong investment recommendation.
AstraZeneca announces EU approval of Imfinzi for muscle-invasive bladder cancer, showing significant survival benefits and addressing critical treatment needs.
Discover AstraZeneca's total voting rights and regulatory compliance in the July 2025 report, vital for shareholders and investor relations.
AstraZeneca PLC announces the approval of Datroway for advanced EGFR-mutated lung cancer, highlighting clinical trial success and strategic collaboration with Daiichi Sankyo.
AstraZeneca's 6-K filing reveals EU approval for Calquence in CLL, showcasing superior trial results and market potential.
Explore AstraZeneca PLC's Form 6-K detailing issued share capital, total voting rights, and regulatory compliance for investors and analysts.